Spillover effects from public and private-sector procurement of medication and treatments likely to continue to benefit pharmaceutical players such as Duopharma Biotech and Kotra Industries, says RHB Research.
PETALING JAYA: The recovery of the healthcare sector in Malaysia is expected to gain further traction over the medium term amid further easing of Covid-19 restrictions.
Hospital service providers, for instance, are witnessing an increase in the number of patients, particularly tourist patients, following the reopening of international borders.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
